In sales revenue in 2010, annual sales revenue of Guangzhou Pharmaceutical Group 27.5 billion, of which 9.2 billion industrial sales, commercial sales of 18.3 billion. Group will constitute the basis of existing business, will break 60 billion revenue goal: compound annual growth rate of not less than 18.01%, to achieve commercial-scale 400 billion target.
in large health industry, the second Five-Year Wanglaoji Guangzhou Pharmaceutical Group will be the core brand, in pharmaceuticals, health products, cosmetics, home medical equipment, beauty, fitness and other areas of diversity, the formation of plant beverages, wine, food and health, drug and cosmetic products and other products.
2 23, Guangzhou Pharmaceutical Group held a Guangzhou Pharmaceutical Group General Manager Li Chuyuan said that by 2015, Guangzhou Pharmaceutical Group will achieve sales revenue of 600 billion yuan or more.
logistics industry, will be based on Guangzhou Pharmaceutical Group's internal resources to achieve centralized procurement, lower costs, speed up the Guangzhou Pharmaceutical Group, a national logistics network system.
Guangzhou Pharmaceutical Group currently has 21 kinds of chemical type, such as a total of 16 kinds of Chinese medicine formulations 1983 different specifications. GAP Group has a nationwide base of 20 herbs, there are a number of research centers and post-doctoral workstations, with South China's largest retail network and pharmaceutical logistics distribution center.
the same time, Li Chuyuan said Guangzhou Pharmaceutical Group will promote the investment of capital as the link acquisition. In need of 10 billion yuan investment on the construction of Guangzhou Pharmaceutical Industrial Park, will be the Group financing; in the industrial expansion, then the horizontal and vertical merger and reorganization, expansion of business areas and industrial scale.
product mix, Guangzhou Pharmaceutical Group will focus on building 100 to 2000 million yuan project at all levels of sub-species. The formation of over a hundred million products group, covering diabetes, cardiovascular, anti-bacterial anti-inflammatory, and other key areas of biological vaccines.
(This article Source: Report of China Securities: Yang Tao)
No comments:
Post a Comment